SG10201506526QA - Halogenated analogues of anti-fibrotic agents - Google Patents

Halogenated analogues of anti-fibrotic agents

Info

Publication number
SG10201506526QA
SG10201506526QA SG10201506526QA SG10201506526QA SG10201506526QA SG 10201506526Q A SG10201506526Q A SG 10201506526QA SG 10201506526Q A SG10201506526Q A SG 10201506526QA SG 10201506526Q A SG10201506526Q A SG 10201506526QA SG 10201506526Q A SG10201506526Q A SG 10201506526QA
Authority
SG
Singapore
Prior art keywords
fibrotic agents
halogenated analogues
analogues
halogenated
fibrotic
Prior art date
Application number
SG10201506526QA
Other languages
English (en)
Inventor
Darren James Kelly
Spencer John Williams
Steven Zammit
Original Assignee
Fibrotech Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrotech Therapeutics Pty Ltd filed Critical Fibrotech Therapeutics Pty Ltd
Publication of SG10201506526QA publication Critical patent/SG10201506526QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00Compounds having —CHO groups
    • C07C47/52Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201506526QA 2007-12-21 2008-12-19 Halogenated analogues of anti-fibrotic agents SG10201506526QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1613407P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
SG10201506526QA true SG10201506526QA (en) 2015-09-29

Family

ID=40800565

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201506526QA SG10201506526QA (en) 2007-12-21 2008-12-19 Halogenated analogues of anti-fibrotic agents

Country Status (12)

Country Link
US (1) US8624056B2 (zh)
EP (2) EP3045170B1 (zh)
JP (2) JP5730578B2 (zh)
KR (2) KR101593708B1 (zh)
CN (2) CN102164887A (zh)
AU (1) AU2008341010B2 (zh)
CA (1) CA2709937C (zh)
MX (1) MX337320B (zh)
NZ (1) NZ584613A (zh)
SG (1) SG10201506526QA (zh)
WO (1) WO2009079692A1 (zh)
ZA (1) ZA201003376B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2035369E (pt) 2006-07-05 2014-09-30 Fibrotech Therapeutics Pty Ltd Compostos terapêuticos
CA2709937C (en) 2007-12-21 2016-03-22 Fibrotech Therapeutics Pty Ltd Halogenated analogues of anti-fibrotic agents
IN2012DN03312A (zh) 2009-10-22 2015-10-23 Fibrotech Therapeutics Pty Ltd
DK3485883T3 (da) * 2010-11-24 2020-10-12 Occurx Pty Ltd Metoder til behandling af øjensygdomme forbundet med betændelse og vaskulær spredning
DK2970383T3 (da) * 2013-03-15 2021-07-05 Univ Texas Fremgangsmåde til behandling af fibrose
JP6932506B2 (ja) * 2013-11-26 2021-09-08 イエール ユニバーシティ 細胞透過組成物およびそれを用いる方法
JP6533997B2 (ja) * 2014-12-26 2019-06-26 株式会社ヤクルト本社 Znf143阻害活性を有する化合物およびその利用
US11014873B2 (en) 2017-02-03 2021-05-25 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
CN110357789B (zh) * 2018-04-11 2022-09-30 华东理工大学 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途
IL305480A (en) * 2021-03-17 2023-10-01 Occurx Pty Ltd Compounds for the treatment of disorders and their salts and polymorphs

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5640710B2 (zh) 1973-01-18 1981-09-22
JPS5830302B2 (ja) * 1974-04-16 1983-06-28 キツセイヤクヒンコウギヨウ カブシキガイシヤ シンキホウコウゾクカルボンサンアミドユウドウタイ ノ セイゾウホウホウ
JPS5848545B2 (ja) 1974-04-18 1983-10-28 キツセイヤクヒンコウギヨウ カブシキガイシヤ シンキホウコウゾクカルボンサンアミドユウドウタイ ノ セイゾウホウホウ
JPS511440A (ja) 1974-04-18 1976-01-08 Kissei Pharmaceutical Shinkihokozokukarubonsanjudotai no seizohoho
GB1484413A (en) 1974-04-18 1977-09-01 Kissei Pharmaceutical Aromatic amidocarboxylic acid derivatives
JPS5576852A (en) 1978-12-01 1980-06-10 Hisamitsu Pharmaceut Co Inc Novel derivative of anthranilic acid
JPS5817186B2 (ja) 1981-01-23 1983-04-05 キツセイ薬品工業株式会社 新規芳香族カルボン酸誘導体の製造方法
JPS5838244A (ja) * 1981-09-01 1983-03-05 Kissei Pharmaceut Co Ltd 核置換シンナモイルアントラニル酸塩およびその製造方法
US4587356A (en) 1981-09-01 1986-05-06 Kissei Pharmaceutical Co., Ltd. Process for the production of nuclear substituted cinnamoylanthranilic acid derivatives
JPS6019754A (ja) 1983-07-14 1985-01-31 Kissei Pharmaceut Co Ltd 芳香族カルボン酸アミド誘導体の製造方法
JPS60152454A (ja) 1984-01-18 1985-08-10 Terumo Corp アミド誘導体およびこれを有効成分として含有する5−リポキシゲナ−ゼ作用阻害剤
JPH07116029B2 (ja) 1989-04-04 1995-12-13 キッセイ薬品工業株式会社 トラニラスト水溶液製剤
EP0468054B1 (en) 1990-02-08 1997-05-28 Eisai Co., Ltd. Benzenesulfonamide derivative
US5248825A (en) 1990-09-20 1993-09-28 Merrell Dow Pharmaceuticals Inc. Calcium uptake inhibitors
ATE167181T1 (de) 1993-12-09 1998-06-15 Ono Pharmaceutical Co Naphthylessigsäurederivate als pgez agonisten und antagonisten
NZ331339A (en) 1996-02-15 2001-02-23 Kissei Pharmaceutical Neovascularization inhibitor comprising N-(3, 4-dimethoxycinnamoyl)anthranilic acid
JPH09278653A (ja) 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
DE19624155A1 (de) 1996-06-18 1998-01-08 Hoechst Ag Substituierte Benzoesäurederivate, Verfahren zu ihrer Herstellung und die Anwendung der Verbindungen zur Behandlung von Krankheiten
JPH10259129A (ja) 1997-01-16 1998-09-29 Kissei Pharmaceut Co Ltd 血管新生阻害剤
FR2759368B1 (fr) 1997-02-10 2001-06-01 Galderma Rech Dermatologique Composes biaromatiques, compositions les contenant et utilisations
JPH10306024A (ja) * 1997-03-07 1998-11-17 Kissei Pharmaceut Co Ltd 糸球体疾患の予防および治療剤
JPH10330254A (ja) 1997-04-01 1998-12-15 Kissei Pharmaceut Co Ltd 翼状片の進行および術後の再発抑制剤
US6127392A (en) 1997-08-05 2000-10-03 American Home Products Corporation Anthranilic acid analogs
DE19935219A1 (de) 1999-07-27 2001-02-01 Boehringer Ingelheim Pharma Carbonsäureamide, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
KR100850330B1 (ko) 2001-02-28 2008-08-04 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 N-(아릴)-2-아릴에텐술폰아미드 및 이를 이용한 약학적 조성물
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
JP4851671B2 (ja) 2001-10-11 2012-01-11 ニチバン株式会社 トラニラスト経皮吸収貼付剤およびその製造方法
PL373484A1 (en) 2001-12-10 2005-09-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MXPA04005864A (es) 2001-12-19 2004-10-29 Atherogenics Inc Derivados de charcona y su uso para tratar enfermedades.
WO2003055847A1 (fr) 2001-12-27 2003-07-10 Taisho Pharmaceutical Co.,Ltd. Derive d'acide carboxylique
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
DE10254872A1 (de) * 2002-11-25 2004-06-03 Symrise Gmbh & Co. Kg Anthranilsäureamide und deren Derivate als kosmetische und pharmazeutische Wirkstoffe
US7250444B2 (en) 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
DE10346913A1 (de) 2003-10-09 2005-05-04 Merck Patent Gmbh Acylhydrazonderivate
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004030987A1 (de) 2004-06-26 2006-01-12 Merck Patent Gmbh Ortho-substituierte (3-Hydroxyphenyl)-essigsäure-benzyliden-hydrazide
US7671077B2 (en) 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto
JP2008518957A (ja) 2004-11-04 2008-06-05 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体作動薬、そのような化合物を含んでいる組成物及び治療方法
WO2006053390A1 (en) 2004-11-17 2006-05-26 Angiogen Pharmaceuticals Pty. Ltd. A method of modulating b cell functioning
CN101061092A (zh) 2004-11-23 2007-10-24 默克公司 烟酸受体激动剂、含有这样化合物的组合物和治疗方法
ITMI20050261A1 (it) 2005-02-21 2006-08-22 Carlo Ghisalberti Analoghi strutturali di avenatramidi loro uso in composizioni utili nel trattamento di disordini dermatologici
AU2006226775A1 (en) 2005-03-24 2006-09-28 Janssen Pharmaceutica, N.V. Biaryl derived amide modulators of vanilloid VR1 receptor
WO2006122353A1 (en) 2005-05-16 2006-11-23 Angiogen Pharmaceuticals Pty. Ltd. Methods and compositions for the treatment of pain
WO2006134013A1 (en) 2005-06-14 2006-12-21 Symrise Gmbh & Co. Kg Mixtures comprising anthranilic acid amides and cooling agents as cosmetic and pharmaceutical compositions for alleviating itching
WO2007015744A1 (en) 2005-07-21 2007-02-08 Incyte Corporation Disubstituted thienyl compounds and their use as pharmaceuticals
US8911795B2 (en) 2005-11-30 2014-12-16 Symrise Ag Compositions comprising dihydroavenanthramide D and climbazole as cosmetic and pharmaceutical compositions for alleviating itching
US20070286892A1 (en) 2006-06-13 2007-12-13 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
ES2462925T3 (es) 2006-06-14 2014-05-26 Symrise Ag Compuestos con efecto antimicrobiano para el tratamiento de fetidez oral
PT2035369E (pt) 2006-07-05 2014-09-30 Fibrotech Therapeutics Pty Ltd Compostos terapêuticos
KR100832747B1 (ko) 2006-10-27 2008-05-27 한국화학연구원 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
EP2030617A1 (en) 2007-08-17 2009-03-04 Sygnis Bioscience GmbH & Co. KG Use of tranilast and derivatives thereof for the therapy of neurological conditions
US20100292283A1 (en) 2007-11-28 2010-11-18 Antonio Nardi Novel phenyl-acetamide and phenyl-propionamide derivatives useful as potassium channel modulators
US20090163586A1 (en) 2007-12-20 2009-06-25 Astrazeneca Ab Bis-(Sulfonylamino) Derivatives in Therapy 205
CA2709937C (en) 2007-12-21 2016-03-22 Fibrotech Therapeutics Pty Ltd Halogenated analogues of anti-fibrotic agents
EP2179984A1 (en) 2008-10-27 2010-04-28 Congenia S.r.l. Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition

Also Published As

Publication number Publication date
AU2008341010A1 (en) 2009-07-02
EP2220028B1 (en) 2016-03-09
EP3045170B1 (en) 2018-07-04
CN107162928A (zh) 2017-09-15
JP2011506490A (ja) 2011-03-03
NZ584613A (en) 2011-07-29
JP5730578B2 (ja) 2015-06-10
EP3045170A1 (en) 2016-07-20
EP2220028A1 (en) 2010-08-25
JP6063985B2 (ja) 2017-01-18
KR20100099134A (ko) 2010-09-10
CN107162928B (zh) 2022-03-11
US20120059188A9 (en) 2012-03-08
CA2709937A1 (en) 2009-07-02
CA2709937C (en) 2016-03-22
CN102164887A (zh) 2011-08-24
AU2008341010B2 (en) 2013-04-18
EP2220028A4 (en) 2011-02-16
WO2009079692A1 (en) 2009-07-02
US20110021815A1 (en) 2011-01-27
MX337320B (es) 2016-01-06
KR101593708B1 (ko) 2016-02-12
US8624056B2 (en) 2014-01-07
MX2010006787A (es) 2010-10-04
ZA201003376B (en) 2011-02-23
JP2015180624A (ja) 2015-10-15
KR20160017139A (ko) 2016-02-15

Similar Documents

Publication Publication Date Title
HUS000509I2 (hu) Abemaciklib vagy egy gyógyászatilag elfogadható sója
ZA201003376B (en) Halogenated analogues of anti-fibrotic agents
EP2308493A4 (en) ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
EP2117311A4 (en) THERAPEUTICS
GB0908957D0 (en) Therapeutic agents
HRP20130041T8 (en) Therapeutic agents
HK1139857A1 (en) Wrinkling-preventing and-modifying agent
GB0723747D0 (en) Therapeutic agents
EP2236594A4 (en) DISPOSAL AGENT OF A BIOLFILM
EP2221057A4 (en) MEANS FOR IMPROVING THE SENSES
SI2424870T1 (sl) Terapevtska sredstva 713
GB0900484D0 (en) Therapeutic agent
EP2168955A4 (en) SLEEP IMPROVEMENT AGENT
GB0709162D0 (en) Dosage foam
EP2140876A4 (en) THERAPEUTIC AGENT COMPRISING VASOHIBINE
GB0701321D0 (en) Agent
EP2172195A4 (en) MEANS OF CHOLESTEROL CONTROL
GB0723748D0 (en) Therapeutic agents
GB0910493D0 (en) Therapeutic agents
GB0623813D0 (en) Foam reduction
AU2009902788A0 (en) Analogues of anti-fibrotic agents
AU2009902966A0 (en) Analogues of anti-fibrotic agents
PL386453A1 (pl) Środek gaśniczy
PL382211A1 (pl) Środek grzybobójczy
PL381418A1 (pl) Pianotwórczy środek gaśniczy